Core Insights - Moderna, Inc. has experienced a significant decline in total revenue from 2023 to date, primarily attributed to the waning demand for its COVID-19 vaccine, SpikeVax [1] Company Overview - Moderna is known for the successful development and commercialization of its COVID-19 vaccine, SpikeVax, which has been a key driver of its revenue in previous years [1] Financial Performance - The company has reported a sharp decline in total revenue, indicating potential challenges in sustaining its financial performance post-pandemic [1]